Posts associated with "BARD1"

image_print

ICARE Social Media Post May 2020

Platinum Based Chemotherapy for Metastatic Pancreatic Cancer

Categories:

Newsletter Articles & Posts

by

A recent study found that patients with metastatic pancreatic cancer who had mutations in the DNA repair genes (either inherited or just in the tumor) had better clinical outcomes after platinum-based chemotherapy compared to patients without these mutations. Check out the link to full article: https://clincancerres.aacrjournals.org/content/early/2020/05/20/1078-0432.CCR-20-0418

Tags: , , , , , , , , , , , , , , , , ,

Permanent link to this article: https://inheritedcancer.net/post52920/

ICARE Newsletter Summer 2018

Updates to NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines

Categories:

Newsletter Articles & Posts

by

(Version 1.2019, posted July 11, 2018) Regardless of family history, some individuals with a hereditary breast- and ovarian-related cancer may benefit from genetic testing to determine eligibility for targeted treatment The multi-gene testing section table was updated with: A potential association of ATM with ovarian cancer risk Potential increased risk of BARD1 with breast cancer …

Continue reading »

Tags: , , , , ,

Permanent link to this article: https://inheritedcancer.net/1nls2018/

ICARE Newsletter Summer 2017

Breast and Ovarian Cancer Associations for Genes Tested Through Multi-Gene Panels

Categories:

Newsletter Articles & Posts

by

As testing for multiple genes at the same time (“multi-gene panel testing”) has become increasingly available with tremendous advances in genetic testing technology, it has become critical to evaluate and refine cancer associations and levels of risk for many of these genes now tested. Through a commercial laboratory database of almost 100,000 results of multi-gene …

Continue reading »

Tags: , , , , , , , , , , , , , , , , , , , , ,

Permanent link to this article: https://inheritedcancer.net/2nls2017/

ICARE Newsletter Summer 2015

2015 NCCN Clinical Practice Guideline Update

Categories:

Newsletter Articles & Posts

by

Breast and Ovarian Management Based on Genetic Test Resultsa   Recommend Breast MRIc (>20% lifetime risk of breast cancerd) Recommend Risk-reducing salpingo-oophorectomy Discuss Option of Risk-reducing mastectomy Intervention warranted based on gene and/or risk level ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, TP53 BRCA1, BRCA2, Lynch syndromee BRCA1, BRCA2, CDH1, PTEN, TP53 Insufficient evidence …

Continue reading »

Tags: , , , , , , , , , , , , , , , ,

Permanent link to this article: https://inheritedcancer.net/1nls2015/